A5101396684- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Cardiac Valve Diseases and Treatments
- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- COVID-19 Clinical Research Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Geometric and Algebraic Topology
- Long-Term Effects of COVID-19
- Advanced Operator Algebra Research
- Chalcogenide Semiconductor Thin Films
- Phase-change materials and chalcogenides
- Autoimmune and Inflammatory Disorders Research
- Cardiac Structural Anomalies and Repair
- Geometry and complex manifolds
- SARS-CoV-2 and COVID-19 Research
- Aortic Disease and Treatment Approaches
- Tryptophan and brain disorders
- Aortic aneurysm repair treatments
- Infective Endocarditis Diagnosis and Management
- Treatment of Major Depression
- Cardiac and Coronary Surgery Techniques
- Diet and metabolism studies
- Cardiac tumors and thrombi
Mount Sinai Health System
2025
Eli Lilly (United States)
2009-2024
Medway NHS Foundation Trust
2024
Sandia National Laboratories
2023
Icahn School of Medicine at Mount Sinai
2007-2017
Beth Israel Deaconess Medical Center
2016
Mayo Clinic in Arizona
2016
Houston Methodist
2016
Mayo Clinic
2016
University of Pittsburgh Medical Center
2016
Degenerative mitral valve repair rates remain highly variable, despite established benefits of over replacement. The contribution surgeon-specific factors is poorly defined. This study evaluated the influence surgeon case volume on degenerative and outcomes. A mandatory New York State database was queried 5,475 patients were identified with disease who underwent operations between 2002 2013. Mitral rates, reoperations within 12 months repair, survival analyzed using multivariable Cox...
We compared the time to discontinuation due lack of tolerability over 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, prodrug metabotropic glutamate 2/3 receptor agonist, LY404039) or standard care (SOC: olanzapine, risperidone, aripiprazole). Study HBBR was a multicenter, randomized, open-label study comparing long-term safety and LY2140023 SOC for schizophrenia. Patients had moderate symptomatology prominent negative symptoms...
Stopping antipsychotic treatment can interrupt improvement and exacerbate the illness. The reasons for discontinuing during controlled clinical trials were analyzed to explore this phenomenon.A post-hoc, pooled analysis was made of 4 randomized, double-blind trials, 24-28 weeks in duration, involving 1627 patients with schizophrenia or a related disorder. Analyses combined all atypical groups studies.The majority (53%) stopped their at an early stage. Poor psychiatric response along...
We tested the hypothesis that long-term treatment with pomaglumetad methionil would demonstrate significantly less weight gain than aripiprazole in patients schizophrenia. In this 24-week, multicenter, randomized, double-blind, Phase 3 study, 678 schizophrenia were randomized to either (n = 516) or 162). Treatment groups also compared on efficacy and various safety measures, including serious adverse events (SAEs), discontinuation due (AEs), treatment-emergent (TEAEs), extrapyramidal...
BackgroundEmpagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess safety efficacy in patients admitted hospital with COVID-19.MethodsIn randomised, controlled, open-label trial, several possible treatments are compared usual care hospitalised COVID-19. In this analysis, we eligible consenting adults who were randomly allocated 1:1 ratio either standard alone or plus oral...
Objective To evaluate ixekizumab safety in adults with psoriatic arthritis (PsA). Methods Safety data from 2 integrated sets are presented: 1) 24‐week, double‐blind, placebo‐controlled period of SPIRIT ‐P1 and ‐P2; 2) all ixekizumab‐treated patients ‐P2 plus ‐P3 open‐label period. We report adverse event ( AE ) frequency exposure‐adjusted incidence rates per 100 patient‐years at 12‐week intervals to week 96. Results The had 678 (safety population): 224 placebo, 229 every 4 weeks, 225 weeks....
Background— Approximately one third of patients with symptomatic aortic stenosis have reduced left ventricular ejection fraction (LVEF) before transcatheter valve replacement. The incidence, predictors, and significance early LVEF recovery after CoreValve replacement not been described. Methods Results— We studied 156 from the Extreme High-Risk trials ≤40% at baseline who had 30-day data. All underwent core laboratory echocardiographic assessment baseline, post procedure, discharge, 30 days,...
ABSTRACT Background The efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard care (SOC) hospitalised adults with COVID-19 is unknown. Methods In this phase 3, global, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries Asia, Europe, North America, South America ( ClinicalTrials.gov NCT04421027 ). Hospitalised receiving SOC randomly assigned (1:1) once-daily baricitinib 4-mg or...
Diagnosis of cardiac myxoma is typically suggested in the presence symptoms and echocardiographic findings an intracardiac mass confirmed histologically. Coronary angiography (CA) magnetic-resonance-imaging (MRI) may provide specific additional information which could lead to a precise preoperative diagnosis. Herein we report series 28 patients who underwent excision between 1998 2005. Data analysis included patient demographics, clinical presentation, imaging modalities, operative outcome....
To determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) compared with lamotrigine (Lam) for long-term treatment bipolar I depression, this 25-wk, randomized, double-blind study OFC (6/25, 6/50, 12/25, or 12/50 mg/d, n=205) Lam titrated to 200 mg/d (n=205) in patients disorder, depressed. A protocol-specified analysis 7-wk outcomes was previously reported. Outcome measures included Clinical Global Impressions – Severity Illness (CGI-S) (primary),...
Objectives The objective of COAST-Y was to evaluate the effect continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission. Methods is an ongoing, phase III, long-term extension study that included a double-blind, placebo (PBO)-controlled, randomised withdrawal-retreatment period (RWRP). Patients completed originating 52-week COAST-V, COAST-W or COAST-X studies entered 24-week lead-in and continued either 80 mg IXE every 2 (Q2W)...
Objective To evaluate the long-term effect of ixekizumab (IXE) on radiographic changes in spine patients with axial spondyloarthritis (r-axSpA) by measuring change from baseline through 2 years modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), and to identify potential predictors progression. Methods This study evaluates COAST-V (ClinicalTrials.gov: NCT02696785 , biologic disease-modifying antirheumatic drug–naïve) COAST-W ( NCT02696798 tumor necrosis factor inhibitor–experienced)...
The outcome of coronary artery bypass grafting (CABG) in diabetic patients has traditionally been worse than non-diabetic patients. Recent studies have suggested an improvement undergoing contemporary CABG. However, the direct impact diabetes on mortality and morbidities following CABG remains unclear. We retrospectively analyzed prospectively collected data 2725 from January 1998 to December 2005: one thousand eighty-five (40%) diabetics 1640 (60%) non-diabetics [mean age 65±11 years, 1882...
Although psoriatic arthritis is complex and involves multiple domains, recent advances in treatments have made remission or near-remission of most symptoms a potentially achievable goal for many patients. We sought to evaluate whether achieving minimal disease activity (MDA) criteria represented meaningful improvement from the patient perspective.Data were combined two randomized, multinational, 24 week clinical studies ixekizumab, high-affinity monoclonal antibody selectively targeting...
Abstract Objective To test association of dopamine receptor D3 (DRD‐3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial. Methods Eighty‐eight acutely ill patients schizophrenia or schizoaffective disorder were genotyped for ser‐9‐gly (rs6280) and 23 other within the DRD‐3 gene. Allelic (mean baseline‐ to‐endpoint reduction Positive Negative Syndrome Scale [PANSS] total subscores) over 6 weeks treatment was assessed using repeated...